Back

Lifetime prediction and Treatment Benefit in HFrEF (LIFE-HF).

26 August 2022 (11:30 - 11:45)
Organised by:
Congress Presentation Part of: Late-Breaking Science - Innovations in drug treatment Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Stefan Koudstaal

Green Heart Hospital, Gouda (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Mechanisms of the clinical benefits of SGLT2i in heart failure (EMPEROR-Pooled)
Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Slides Video
Presentation thumbnail
Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI Randomised Trial
Doctor B. Ingraham (Rochester, US)
Slides Video
Presentation thumbnail
ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.
Professor D. Bhatt (New York City, US)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science - Innovations in drug treatment
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 11:30 CET
You may be interested in
thumbnail
Congress Presentation
Validation of a HFrEF individual lifetime risk calculator in the Portuguese population
thumbnail
Congress Presentation
A novel risk score incorporating frailty or congestion status predicted mortality in patients with heart failure with preserved ejection fraction.
thumbnail
Congress Presentation
Development of a predictive model for adverse cardiovascular events in patients with heart failure from a real-world population in a regional hospital in portugal

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources